EP1492538A1 - Meloxicam suppositories containing e.g. polyethylenglycol - Google Patents
Meloxicam suppositories containing e.g. polyethylenglycolInfo
- Publication number
- EP1492538A1 EP1492538A1 EP03714899A EP03714899A EP1492538A1 EP 1492538 A1 EP1492538 A1 EP 1492538A1 EP 03714899 A EP03714899 A EP 03714899A EP 03714899 A EP03714899 A EP 03714899A EP 1492538 A1 EP1492538 A1 EP 1492538A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- suppository
- meloxicam
- composition
- polyethylenglycol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 40
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960001929 meloxicam Drugs 0.000 title claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 38
- 239000002904 solvent Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 3
- LICPKMHUPOIPDE-WZTVWXICSA-N 4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 LICPKMHUPOIPDE-WZTVWXICSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000002511 suppository base Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- FKOSZDBJQBJDIV-UHFFFAOYSA-N 2h-1,2-benzothiazine-3-carboxamide Chemical compound C1=CC=C2SNC(C(=O)N)=CC2=C1 FKOSZDBJQBJDIV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to a suppository essentially consisting of the active ingredient meloxicam or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
- Meloxicam [2H-1 ,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2- thiazolyl)-1 ,1 -dioxide] is a non-steroidal antiinflammatory drug (NSAID) with antiinflammatory, antipyretic and analgetic activity. Rectal absorption of Meloxicam has been reported (Arzneistoffforschung 47, 3, 253,
- a suppository base and a solubilizer affect the stability, release and absorption of a drug.
- meloxicam is formulated in different suppository bases e.g. Witepsol H15 in combination with PVP K90.
- the drug release of this formulation is comparable with commercially available meloxicam suppositories.
- the problem underlying the present invention is to provide a meloxicam suppository, which shows a fast onset of meloxicam absorption and a high bioavailability of meloxicam.
- a suppository containing a composition, essentially consisting of meloxicam or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein at least one of the excipients is a polyalkylenglycol.
- pharmaceutically acceptable salt stands for a meloxicam salt of an organic or inorganic base, as for example the meglumin, sodium, potassium or ammonium salt.
- the Polyalkylenglycols are as a rule Polyethylenglycols, Polypropylenglycols, or mixtures thereof, preferably Polyethylenglycols.
- the Polyethylenglycol component typically has an average molecular weight from about 200 to about 6000.
- Commercially available Polyethylenglycol materials include e.g. PEG 400, PEG 800, PEG 1000,
- the present invention relates to a suppository, wherein the suppository is a soft gelatine capsule suitable for rectal administration.
- the present invention relates to a suppository wherein the composition comprises the meloxicam meglumin salt.
- the present invention relates to a suppository wherein the composition comprises the free meloxicam base.
- the present invention relates to a suppository, wherein the polyalkylenglycol is selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000.
- the present invention relates to a suppository which contains 0.1 % by weight or more, preferably 0.1 % to 5 %, more preferably about 0.3% of a solubilizer or a mixture of solubilizers of the overall weight of said composition.
- solubilizers are preferably selected from the group consisting of sodium hydroxide, potasium hydroxide, sodium bicarbonate, sodium citrate, and Meglumin. ln a further particularly preferred embodiment the present invention relates to a suppository, wherein the composition contains 1 to 20 /vg, preferably 3 to 15 /vg, more preferably about 5 to 10 vg, of the free meloxicam base per mg of said composition.
- the present invention relates to a suppository which contains at least 0.2 mg, preferably 0.2 to 5 mg, more preferably about 1 mg, of the solubilizer or mixture of solubilizers per mg of the free meloxicam base.
- a suppository which contains a composition consisting of a) 1 to 20 mg, preferably 3 to 15 mg, more preferably about 5 to 10 mg, of meloxicam, b) 500 to 1500 mg, preferably 800 to 1200 mg, more preferably about 1000 mg, of one or more polyalkylenglycols selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000, and optionally c) one or two additional excipients, e.g. a solubilizer, preferably meglumine or a stabilizer.
- a solubilizer preferably meglumine or a stabilizer.
- a method for preparation of said suppository comprises the steps of a) intimately mixing of meloxicam or a pharmaceutically acceptable salt thereof with the melted solubilizer, and b) encapsulating or molding of the composition obtained in step a) by a conventional method, for example described in "Suppositories -From Dosage Forms to Clinical Applications-", Nanzando co., Ltd. 1985.
- the suppository of the present invention is used for the preparation of a medicament with enhanced bioavailability for the treatment or prevention of polyarthritis, rheumatoid arthritis or inflammation deseases.
- the invention will be further illustrated by the examples of suppository compositions given in Table 1. The invention should not be limited to these examples.
- the compositions B & C are manufactured to suppositories by conventional methods, which are described for instance in "Suppositories -From Dosage Forms to Clinical Applications-", Nanzando co., Ltd. 1985.
- a suitable method of manufacturing a composition according to the invention is e.g. to dispense each component of the composition in the suppository base, e.g. a polyethylenglycol.
- a suitable vessel such as a stainless steel beaker, at room temperature. The mixture is stirred for about 0.5 hours, until a clear solution is obtained.
- Bioavailability tests have been conducted with suppository formulations according to the present invention and with a commercially available meloxicam formulation.
- the composition of the tested Meloxicam suppository formulation is based on fats such as Suppocire BP.
- the plasma concentration test is conducted using beagle dogs. Six to nine suppositories were tested for each batch.
- compositions according to the invention were found to be superior to the fat based composition regarding the onset of meloxicam absorption and the bioavailability of meloxicam.
- Stability tests have been conducted with formulation type A at 30 °C, 70 % room humidity over six month in a PVC/aluminium pillow. Details of the stability test can be • found in Table 2.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a suppository essentially consisting of the active ingredient meloxicam or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
Description
MELOXICAM SUPPOSITORIES CONTAINING E.G. POLYETHYLENGLYCOI*
Field of the invention
The present invention relates to a suppository essentially consisting of the active ingredient meloxicam or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
Background of the invention
Meloxicam [2H-1 ,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2- thiazolyl)-1 ,1 -dioxide] is a non-steroidal antiinflammatory drug (NSAID) with antiinflammatory, antipyretic and analgetic activity. Rectal absorption of Meloxicam has been reported (Arzneimittelforschung 47, 3, 253,
1997). The type and nature of a suppository base and a solubilizer affect the stability, release and absorption of a drug.
The formulation of meloxicam suppositories is desribed in J. Pharm. Sci. (Vol.23, 11 ,
June 1999), wherein meloxicam is formulated in different suppository bases e.g. Witepsol H15 in combination with PVP K90. The drug release of this formulation is comparable with commercially available meloxicam suppositories.
Description of the invention
The problem underlying the present invention is to provide a meloxicam suppository, which shows a fast onset of meloxicam absorption and a high bioavailability of meloxicam.
Thus it has surprisingly been found that the problem underlying the invention is solved by a suppository containing a composition, essentially consisting of meloxicam or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein at least one of the excipients is a polyalkylenglycol.
According to the invention the term pharmaceutically acceptable salt stands for a meloxicam salt of an organic or inorganic base, as for example the meglumin, sodium, potassium or ammonium salt.
The Polyalkylenglycols are as a rule Polyethylenglycols, Polypropylenglycols, or mixtures thereof, preferably Polyethylenglycols.
The Polyethylenglycol component typically has an average molecular weight from about 200 to about 6000. Commercially available Polyethylenglycol materials, for example from Nippon Yushi Co., Ltd., include e.g. PEG 400, PEG 800, PEG 1000,
PEG 2000, PEG 3000, PEG 4000 and PEG 6000.
In a preferred embodiment the present invention relates to a suppository, wherein the suppository is a soft gelatine capsule suitable for rectal administration.
In a further preferred embodiment the present invention relates to a suppository wherein the composition comprises the meloxicam meglumin salt.
In a further preferred embodiment the present invention relates to a suppository wherein the composition comprises the free meloxicam base.
In a particularly preferred embodiment the present invention relates to a suppository, wherein the polyalkylenglycol is selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000.
In a further particularly preferred embodiment the present invention relates to a suppository which contains 0.1 % by weight or more, preferably 0.1 % to 5 %, more preferably about 0.3% of a solubilizer or a mixture of solubilizers of the overall weight of said composition.
According to the invention solubilizers are preferably selected from the group consisting of sodium hydroxide, potasium hydroxide, sodium bicarbonate, sodium citrate, and Meglumin.
ln a further particularly preferred embodiment the present invention relates to a suppository, wherein the composition contains 1 to 20 /vg, preferably 3 to 15 /vg, more preferably about 5 to 10 vg, of the free meloxicam base per mg of said composition.
In another particularly preferred embodiment the present invention relates to a suppository which contains at least 0.2 mg, preferably 0.2 to 5 mg, more preferably about 1 mg, of the solubilizer or mixture of solubilizers per mg of the free meloxicam base.
More particularly preferred according to the present invention is a suppository, which contains a composition consisting of a) 1 to 20 mg, preferably 3 to 15 mg, more preferably about 5 to 10 mg, of meloxicam, b) 500 to 1500 mg, preferably 800 to 1200 mg, more preferably about 1000 mg, of one or more polyalkylenglycols selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000, and optionally c) one or two additional excipients, e.g. a solubilizer, preferably meglumine or a stabilizer.
As a rule according to the invention a method for preparation of said suppository comprises the steps of a) intimately mixing of meloxicam or a pharmaceutically acceptable salt thereof with the melted solubilizer, and b) encapsulating or molding of the composition obtained in step a) by a conventional method, for example described in "Suppositories -From Dosage Forms to Clinical Applications-", Nanzando co., Ltd. 1985.
The suppository of the present invention is used for the preparation of a medicament with enhanced bioavailability for the treatment or prevention of polyarthritis, rheumatoid arthritis or inflammation deseases.
The invention will be further illustrated by the examples of suppository compositions given in Table 1. The invention should not be limited to these examples. According to the present invention the compositions B & C are manufactured to suppositories by conventional methods, which are described for instance in "Suppositories -From Dosage Forms to Clinical Applications-", Nanzando co., Ltd. 1985. A suitable method of manufacturing a composition according to the invention is e.g. to dispense each component of the composition in the suppository base, e.g. a polyethylenglycol. Subsequently all components are mixed in a suitable vessel, such as a stainless steel beaker, at room temperature. The mixture is stirred for about 0.5 hours, until a clear solution is obtained.
Table 1. Compositions of meloxicam for suppositories
Bioavailability tests have been conducted with suppository formulations according to the present invention and with a commercially available meloxicam formulation. The composition of the tested Meloxicam suppository formulation is based on fats such as Suppocire BP. The plasma concentration test is conducted using beagle dogs. Six to nine suppositories were tested for each batch.
The tested suppositories were prepared from the compositions shown in Table 1. Test results are shown in Fig. 1.
Compositions according to the invention were found to be superior to the fat based composition regarding the onset of meloxicam absorption and the bioavailability of meloxicam.
Stability tests have been conducted with formulation type A at 30 °C, 70 % room humidity over six month in a PVC/aluminium pillow. Details of the stability test can be • found in Table 2.
Table 2. Stability Test
In both samples the meloxicam content and the packaging material were found to be unchanged.
Claims
1. A suppository containing a composition, essentially consisting of meloxicam or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, characterized in that at least one of the excipients is a polyalkylenglycol.
2. A suppository capsule according to claim 1 , characterized in that the suppository is a soft gelatine capsule suitable for rectal administration.
3. A suppository capsule according to claim 1 or 2, characterized in that the composition comprises the meloxicam meglumin salt.
4. A suppository capsule according to claim 1 or 2, characterized in that the composition comprises the free meloxicam base.
5. A suppository according to claim 1 to 4, characterized in that the polyalkylenglycol is selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000.
6. A suppository according to claim 1 to 5 characterized in that it contains 0.1 % by weight or more of a solubilizer or a mixture of solubilizers of the overall weight of said composition.
7. A suppository according to claim 1 to 6 characterized in that the composition contains 1 to 20 /vg of the free meloxicam base per mg of the composition.
8. A suppository according to claim 1 to 7 characterized in that the composition contains at least 0.2 mg of the solubilizer or mixture of solubilizers per mg of the free meloxicam base.
. A suppository according to claim 1 to 8 which contains a composition consisting of a) 1 to 20 mg of meloxicam, b) 500 to 1500 mg of a one or more polyalkylenglycols selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000, and optionally c) one or two additional excipients.
10. A method for preparation of a suppository according to claim 1 to 9, which comprises the steps of a) intimately mixing of meloxicam or a pharmaceutically acceptable salt thereof with the melted solubilizer, and b) encapsulating or molding of the composition obtained in step a) by a conventional method.
11. Use of a suppository according to claim 1 to 9 for the preparation of a medicament with enhanced bioavailability for the treatment or prevention of polyarthritis, rheumatoid arthritis or inflammation deseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03714899A EP1492538A1 (en) | 2002-03-30 | 2003-03-28 | Meloxicam suppositories containing e.g. polyethylenglycol |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02007455 | 2002-03-30 | ||
| EP02007455A EP1348436A1 (en) | 2002-03-30 | 2002-03-30 | Meloxicam suppositories |
| EP03714899A EP1492538A1 (en) | 2002-03-30 | 2003-03-28 | Meloxicam suppositories containing e.g. polyethylenglycol |
| PCT/EP2003/003252 WO2003082297A1 (en) | 2002-03-30 | 2003-03-28 | Meloxicam suppositories containing e.g. polyethylenglycol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1492538A1 true EP1492538A1 (en) | 2005-01-05 |
Family
ID=27798842
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02007455A Withdrawn EP1348436A1 (en) | 2002-03-30 | 2002-03-30 | Meloxicam suppositories |
| EP03714899A Withdrawn EP1492538A1 (en) | 2002-03-30 | 2003-03-28 | Meloxicam suppositories containing e.g. polyethylenglycol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02007455A Withdrawn EP1348436A1 (en) | 2002-03-30 | 2002-03-30 | Meloxicam suppositories |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1348436A1 (en) |
| JP (1) | JP2005521714A (en) |
| AR (1) | AR039184A1 (en) |
| AU (1) | AU2003219113A1 (en) |
| CA (1) | CA2479914A1 (en) |
| PE (1) | PE20040308A1 (en) |
| TW (1) | TW200306862A (en) |
| UY (1) | UY27741A1 (en) |
| WO (1) | WO2003082297A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10161077A1 (en) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Highly concentrated stable meloxicam solutions for needleless injection |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| ES3037313T3 (en) | 2009-10-12 | 2025-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| MX2012010077A (en) | 2010-03-03 | 2012-09-12 | Boehringer Ingelheim Vetmed | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats. |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2756113A1 (en) * | 1977-12-16 | 1979-06-21 | Thomae Gmbh Dr K | NEW 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THESE |
| JPH0816051B2 (en) * | 1988-12-07 | 1996-02-21 | エスエス製薬株式会社 | Sustained release suppositories |
| JPH04346928A (en) * | 1991-05-24 | 1992-12-02 | Doujin Iyaku Kako Kk | Suppository |
| JPH07100191A (en) * | 1993-10-06 | 1995-04-18 | Daikyo Yakuhin Kogyo Kk | Sustained release suppository |
| EP0839029A1 (en) * | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
| CA2301304A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| EP0945134A1 (en) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | New galenic formulations of meloxicam for oral administration |
| DE10030345A1 (en) * | 2000-06-20 | 2002-01-10 | Boehringer Ingelheim Vetmed | Highly concentrated stable meloxicam solutions |
-
2002
- 2002-03-30 EP EP02007455A patent/EP1348436A1/en not_active Withdrawn
-
2003
- 2003-03-28 EP EP03714899A patent/EP1492538A1/en not_active Withdrawn
- 2003-03-28 PE PE2003000319A patent/PE20040308A1/en not_active Application Discontinuation
- 2003-03-28 JP JP2003579834A patent/JP2005521714A/en active Pending
- 2003-03-28 CA CA002479914A patent/CA2479914A1/en not_active Abandoned
- 2003-03-28 UY UY27741A patent/UY27741A1/en not_active Application Discontinuation
- 2003-03-28 TW TW092107120A patent/TW200306862A/en unknown
- 2003-03-28 AU AU2003219113A patent/AU2003219113A1/en not_active Abandoned
- 2003-03-28 AR ARP030101097A patent/AR039184A1/en unknown
- 2003-03-28 WO PCT/EP2003/003252 patent/WO2003082297A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO03082297A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040308A1 (en) | 2004-07-06 |
| AR039184A1 (en) | 2005-02-09 |
| WO2003082297A1 (en) | 2003-10-09 |
| JP2005521714A (en) | 2005-07-21 |
| EP1348436A1 (en) | 2003-10-01 |
| UY27741A1 (en) | 2003-10-31 |
| AU2003219113A1 (en) | 2003-10-13 |
| TW200306862A (en) | 2003-12-01 |
| CA2479914A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8383150B2 (en) | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients | |
| CA2234140C (en) | Stable freeze-dried pharmaceutical formulation | |
| JP5330347B2 (en) | Stable high concentration meloxicam solution | |
| EP1319397B1 (en) | Suppositories sustained in the lower rectum | |
| CZ312794A3 (en) | Erodizable pharmaceutical preparation | |
| EP2037887B1 (en) | Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor | |
| KR100311165B1 (en) | Pharmaceutical composition for treating depression containing pramifelsol | |
| JP2006514052A (en) | Solid dispersant containing hygroscopic and / or deliquescent agent | |
| US20040001883A1 (en) | Meloxicam suppositories | |
| EP1348436A1 (en) | Meloxicam suppositories | |
| KR101679380B1 (en) | Pharmaceutical composition including dutasteride and capsule formulation comprising the same | |
| KR920001459B1 (en) | Process for preparing nifedipine composition | |
| KR19980701292A (en) | Resin particle, medical material and pharmaceutical preparation containing said resin particle | |
| EP1713442A1 (en) | Semisolid matrix pharmaceutical formulations | |
| EP1944028B1 (en) | Solid oral forms of ebastine | |
| EA200101108A1 (en) | POLYMORPHIC MODIFICATIONS OF AZABICYCLO [2.2.2] OKTAN-3-AMINE AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| WO2020009394A1 (en) | Pharmaceutical composition containing extract of pelargonium sidoides, and preparation method therefor | |
| AU2013201986B2 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
| CA2100836E (en) | Pharmaceutical composition | |
| JPS6235A (en) | Composition for rectal administration of calcitonin | |
| AU2014240300B2 (en) | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients | |
| WO2019138424A1 (en) | Stable pharmaceutical compositions comprising lenalidomide | |
| KR20060095663A (en) | Novel Clotrimazole Vaginal Suppository Compositions | |
| JP2017222728A (en) | Fenofibrate solid dispersion | |
| KR20010018892A (en) | Antifungal composition comprising itraconazole and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041102 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| 17Q | First examination report despatched |
Effective date: 20080422 |
|
| RTI1 | Title (correction) |
Free format text: MELOXICAM SUPPOSITORIES CONTAINING POLYETHYLENGLYCOL |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090811 |